Foghorn Therapeutics, Inc. (FHTX)
1.76
-0.02
(-1.12%)
USD |
NASDAQ |
Nov 20, 10:20
Foghorn Therapeutics Free Cash Flow : -83.68M for Sept. 30, 2026
Free Cash Flow Chart
Historical Free Cash Flow Data
| Date | Value |
|---|---|
| September 30, 2026 | -83.68M |
| June 30, 2026 | -84.29M |
| March 31, 2026 | -87.42M |
| December 31, 2025 | -86.15M |
| September 30, 2025 | -88.88M |
| June 30, 2025 | -91.33M |
| March 31, 2025 | -95.86M |
| December 31, 2024 | -101.31M |
| September 30, 2024 | -103.89M |
| June 30, 2024 | -109.87M |
| March 31, 2024 | -116.96M |
| Date | Value |
|---|---|
| December 31, 2023 | -119.33M |
| September 30, 2023 | -120.94M |
| June 30, 2023 | -113.97M |
| March 31, 2023 | -110.70M |
| December 31, 2022 | 192.40M |
| September 30, 2022 | 233.40M |
| June 30, 2022 | 232.98M |
| March 31, 2022 | 242.66M |
| December 31, 2021 | -53.56M |
| September 30, 2021 | -83.51M |
Free Cash Flow Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Free Cash Flow Benchmarks
| Anavex Life Sciences Corp. | -29.29M |
| Vaxcyte, Inc. | -994.76M |
| Connect Biopharma Holdings Ltd. | -56.12M |
| Caribou Biosciences, Inc. | -92.99M |
| Oncolytics Biotech, Inc. | -28.39M |
Free Cash Flow Related Metrics
| Cash from Operations (Quarterly) | -18.24M |
| Cash from Investing (Quarterly) | 24.19M |
| Cash from Financing (Quarterly) | 6.276M |
| Free Cash Flow Per Share (Quarterly) | -0.2514 |
| Free Cash Flow to Equity (Quarterly) | -19.02M |
| Free Cash Flow to Firm (Quarterly) | -18.25M |
| Free Cash Flow Yield | -79.29% |